Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale

on behalf of the AL-108-231 Investigators

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. Methods: We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated “a little worse” and those rated “unchanged” on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. Results: The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. Conclusions: Clinically meaningful change is measurable on the PSPRS over 6 months.

Original languageEnglish (US)
Pages (from-to)1574-1577
Number of pages4
JournalMovement Disorders
Volume31
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Progressive Supranuclear Palsy
Activities of Daily Living
Multivariate Analysis
Logistic Models
Clinical Trials

Keywords

  • minimal clinically important change (MCIC)
  • progressive supranuclear palsy (PSP)
  • progressive supranuclear palsy rating scale (PSPRS)

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. / on behalf of the AL-108-231 Investigators.

In: Movement Disorders, Vol. 31, No. 10, 01.10.2016, p. 1574-1577.

Research output: Contribution to journalArticle

on behalf of the AL-108-231 Investigators. / Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. In: Movement Disorders. 2016 ; Vol. 31, No. 10. pp. 1574-1577.
@article{e7d3e81ed1674815bf8007d441775bc6,
title = "Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale",
abstract = "Background: Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. Methods: We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated “a little worse” and those rated “unchanged” on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. Results: The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. Conclusions: Clinically meaningful change is measurable on the PSPRS over 6 months.",
keywords = "minimal clinically important change (MCIC), progressive supranuclear palsy (PSP), progressive supranuclear palsy rating scale (PSPRS)",
author = "{on behalf of the AL-108-231 Investigators} and Sarah Hewer and Sue Varley and Boxer, {Adam L.} and Eldho Paul and Williams, {David R.} and Azulay, {Jean Phllippe} and Reiner Benecke and Boeve, {Bradley F.} and Bordelon, {Yvette M.} and Boxer, {Adam L.} and Bruce Miller and Burn, {David J.} and Dennis Chan and Corvol, {Jean Christophe} and Philippe Couratier and Praveen Dayalu and Rachelle Doody and Erika Driver-Dunkley and Joseph Ferrara and Golbe, {Lawrence I.} and Graff-Radford, {Neill R.} and David Grimes and Murray Grossman and Steven Gunzler and Hillis, {Argyle Elizabeth} and G{\"u}nter H{\"o}glinger and Lawrence Honig and Anthony Lang and Andrew Lees and Irene Litvan and Isaacson, {Stuart H.} and Joseph Jankovic and Jog, {Mandar S.} and Kaufer, {Daniel I.} and Rajeev Kumar and Lafontaine, {Anne Louise} and Julie Leegwater-Kim and Stephanie Lessig and Lew, {Mark F.} and Axel Lipp and Iryna Lobach and Lorenzl, {Stefan P.} and Albert Ludolph and Connie Marras and Scott McGinnis and Brit Mollenhauer and Rajesh Pahwa and Michel Panisset and Heinz Reichmann and Tao Xie",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/mds.26694",
language = "English (US)",
volume = "31",
pages = "1574--1577",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale

AU - on behalf of the AL-108-231 Investigators

AU - Hewer, Sarah

AU - Varley, Sue

AU - Boxer, Adam L.

AU - Paul, Eldho

AU - Williams, David R.

AU - Azulay, Jean Phllippe

AU - Benecke, Reiner

AU - Boeve, Bradley F.

AU - Bordelon, Yvette M.

AU - Boxer, Adam L.

AU - Miller, Bruce

AU - Burn, David J.

AU - Chan, Dennis

AU - Corvol, Jean Christophe

AU - Couratier, Philippe

AU - Dayalu, Praveen

AU - Doody, Rachelle

AU - Driver-Dunkley, Erika

AU - Ferrara, Joseph

AU - Golbe, Lawrence I.

AU - Graff-Radford, Neill R.

AU - Grimes, David

AU - Grossman, Murray

AU - Gunzler, Steven

AU - Hillis, Argyle Elizabeth

AU - Höglinger, Günter

AU - Honig, Lawrence

AU - Lang, Anthony

AU - Lees, Andrew

AU - Litvan, Irene

AU - Isaacson, Stuart H.

AU - Jankovic, Joseph

AU - Jog, Mandar S.

AU - Kaufer, Daniel I.

AU - Kumar, Rajeev

AU - Lafontaine, Anne Louise

AU - Leegwater-Kim, Julie

AU - Lessig, Stephanie

AU - Lew, Mark F.

AU - Lipp, Axel

AU - Lobach, Iryna

AU - Lorenzl, Stefan P.

AU - Ludolph, Albert

AU - Marras, Connie

AU - McGinnis, Scott

AU - Mollenhauer, Brit

AU - Pahwa, Rajesh

AU - Panisset, Michel

AU - Reichmann, Heinz

AU - Xie, Tao

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background: Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. Methods: We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated “a little worse” and those rated “unchanged” on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. Results: The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. Conclusions: Clinically meaningful change is measurable on the PSPRS over 6 months.

AB - Background: Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. Methods: We analyzed data from a large clinical trial in PSP-Richardson's syndrome (AL-108-231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated “a little worse” and those rated “unchanged” on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. Results: The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. Conclusions: Clinically meaningful change is measurable on the PSPRS over 6 months.

KW - minimal clinically important change (MCIC)

KW - progressive supranuclear palsy (PSP)

KW - progressive supranuclear palsy rating scale (PSPRS)

UR - http://www.scopus.com/inward/record.url?scp=84991274857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991274857&partnerID=8YFLogxK

U2 - 10.1002/mds.26694

DO - 10.1002/mds.26694

M3 - Article

C2 - 27324431

AN - SCOPUS:84991274857

VL - 31

SP - 1574

EP - 1577

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 10

ER -